

We claim:

1. An antibody or antibody fragment thereof, wherein said antibody comprises a variable heavy chain amino acid sequence of SEQ ID NO. 50 and a variable light chain amino acid sequence of SEQ ID NO. 48.
- 5 2. The antibody according to Claim 1, wherein said antibody is monoclonal.
3. The monoclonal antibody according to Claim 2, wherein said monoclonal antibody is a chimeric antibody, humanized antibody, or fully human antibody.
- 10 4. The antibody fragment according to Claim 1, wherein said antibody fragment is a Fab fragment, (Fab')₂ fragment, or Fv fragment.
5. The antibody according to Claim 1, wherein said antibody is conjugated to a cytotoxic agent.
- 15 6. A pharmaceutical composition comprising the antibody or antibody fragment according to Claim 1 and a physiologically acceptable pharmaceutical carrier.
7. A method of preventing or reducing severity of at least one symptom of an inflammatory bowel disease in a subject in need thereof, comprising administering to said subject an effective amount of an antibody or antibody fragment according to Claim 1.
- 20 8. The method according to Claim 7, wherein said inflammatory bowel disease is Crohn's disease or ulcerative colitis.
9. The method according to Claim 7, wherein said antibody inhibits at least one biological activity of IP-10.
- 25 10. The method according to Claim 7, further comprises administering an immunosuppressive agent to the subject.

11. An antibody or antibody fragment thereof, wherein said antibody comprises a variable heavy chain amino acid sequence of SEQ ID NO. 78 and a variable light chain amino acid sequence of SEQ ID NO. 48.
12. The antibody according to Claim 11, wherein said antibody is monoclonal.
13. The monoclonal antibody according to Claim 12, wherein said monoclonal antibody is a chimeric antibody, humanized antibody, or fully human antibody.
14. The antibody fragment according to Claim 11, wherein said antibody fragment is a Fab fragment, (Fab')₂ fragment, or Fv fragment.
15. The antibody according to Claim 11, wherein said antibody is conjugated to a cytotoxic agent.
16. A pharmaceutical composition comprising the antibody or antibody fragment according to Claim 11 and a physiologically acceptable pharmaceutical carrier.
17. A method of preventing or reducing severity of at least one symptom of an inflammatory bowel disease in a subject in need thereof, comprising administering to said subject an effective amount of an antibody or antibody fragment according to Claim 11.
18. The method according to Claim 17, wherein said inflammatory bowel disease is Crohn's disease or ulcerative colitis.
19. The method according to Claim 17, wherein said antibody inhibits at least one biological activity of IP-10.
20. The method according to Claim 17, further comprises administering an immunosuppressive agent to the subject.